Arca
Skip to content

Primary immunodeficiency diseases

Drug research and approvals for primary immunodeficiency diseases: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 78 studies of primary immunodeficiency diseases are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 78
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 78 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Apr 10, 2024Phase Ib open label basket trial of ray121 to inhibit classical complement pathway in immunological diseases (rainbow trial)RAY121Chugai PharmaceuticalOngoing
Apr 3, 2019"a phase III, open-label, prospective, multicenter study to assess efficacy, safety and pharmacokinetics of kedrion intravenous immunoglobulin (ivig) 10% in…HUMAN IMMUNOGLOBULIN, 10% SOLUTIONKEDRION S.P.A.Closed
Oct 30, 2017Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (octanorm) in patients with primary…OCTANORM 16.5%OCTAPHARMA CANADA INCOngoing
Oct 23, 2015An open-label, multi-center study to evaluate the safety and pharmacokinetics of igsc 20% administered for 6 months in subjects with primary immunodeficiencyIGSC 20%, IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN), 20% CAPRYLATE/CHROMATOGRAPHY…GrifolsOngoing
Oct 2, 2014Clinical phase III study to evaluate the pharmacokinetics, efficacy, tolerability and safety of subcutaneous human immunoglobulin (octanorm 16.5%) in patients…OCTANORM 16.5%OCTAPHARMA CANADA INCOngoing
Dec 12, 2013Reducing-intensity conditioning for children and adults with hemophagocytic syndromes or selected primary immune deficiencies (richi)FLUDARABINE / MABCAMPATH (ALEMTUZUMAB) / MELPHALAN / METHYLPREDNISOLONE /…C17Ongoing
Jun 27, 2013A clinical study of immune globulin subcutaneous (human) 20% solution (igsc,20%) for the evaluation of efficacy, safety, tolerability and pharmacokinetics in…IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN), 20% SOLUTION (IGSC, 20%)Baxter InternationalPending

Medicines Authorised in the EU

Newest first
May 21, 2026Joenjaleniolisib · orphanPharming Technologies B.V.EMA ↗
Apr 27, 2026Xolremdimavorixafor · orphanNorgine B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.